Key Takeaways Medicare and Medicaid will cover drugs used for weight loss for the first time, offering Wegovy, Zepbound, Monjauro, and Ozempic for $50 a month co-pays.The White House negotiated lower prices from Eli Lilly and Novo Nordisk,

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with obesity, President Trump announced on Thursday.

Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will be available at reduced prices,

Medicare cover GLP-1s under a Trump-negotiated pricing plan starting in 2026, lowering costs for key obesity and diabetes drugs.